logo
Plus   Neg
Share
Email

5 Top Losers In Healthcare Sector (PTI, REPH, BPTH...)

pharmadown-march25-lt.jpg

The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

1. Proteostasis Therapeutics Inc. (PTI)

Lost 67.81% to close Monday's (Mar.25) trading at $1.31.

News: The Company announced results from Phase 1 clinical studies of its proprietary triple combination therapy of PTI-808, PTI-801, and PTI-428, as well as separate studies of PTI-801 in cystic fibrosis subjects.

Analysts who compared the trial results of Proteostasis' combination therapy and Vertex's VX-659 triple combination regimen say that Vertex's combination regimen is more promising than that of Proteostasis.

2. Recro Pharma Inc. (REPH)

Lost 33.85% to close Monday's trading at $6.41.

News: The Company's New Drug Application seeking approval for intravenous (IV) Meloxicam for the management of moderate to severe pain has been rejected by the FDA again.

In its Complete Response Letter (CRL), the FDA has noted that the delayed onset of IV meloxicam fails to meet the prescriber expectations for intravenous (IV) drugs. The CRL also cited regulatory concerns about the role of IV meloxicam as a monotherapy in acute pain, as well as how it would meet patient and prescriber needs in that setting, given the FDA's interpretation of the clinical trials data.

3. Motif Bio plc (MTFB)

Lost 15.56% to close Monday's trading at $1.90.

News: No news

Upcoming event:

On May 3, 2019, the Company will be meeting with the FDA to discuss the points raised in the Complete Response Letter related to Iclaprim for the treatment of acute bacterial skin and skin structure infections.

In its Complete Response Letter issued for Iclaprim on February 14, 2019, the FDA had sought additional data before the drug could be approved.

4. Apollo Endosurgery Inc. (APEN)

The Company deals with less invasive medical devices for bariatric and gastrointestinal procedures. The marketed products include OverStitch Endoscopic Suturing System and ORBERA Intragastric Balloon.

Lost 13.75% to close Monday's trading at $3.45.

News: No news

Recent event:

On March 18, 2019, the Company announced financial results for the fourth quarter and year ended December 31, 2018.

Net loss for the fourth quarter of 2018 widened to $18.4 million or $0.84 per share from $7.3 million or $0.42 per share for the fourth quarter of 2017. Revenues in the fourth quarter of 2018 declined to $15.18 million from $16.14 million in the year-ago quarter.

5. Bio-Path Holdings Inc. (BPTH)

Lost 12.42% to close Monday's trading at $19.25.

The stock has been on a roll after the Company announced an update to its phase II trial of Prexigebersen for the treatment of acute myeloid leukemia on March 6. Now, the stock is giving back some of its gains.

News: No news

Recent events:

-- On March 6, the Company provided a clinical update to the previously reported interim analysis from Stage 1 of its phase II trial of Prexigebersen for the treatment of acute myeloid leukemia, revealing an improvement in efficacy profile and strong evidence of safety profile. The news sent the stock up 160% that day. The following day, i.e., on March 7, the stock touched an intraday high of $73.52, before closing at $38.86.

The Stage 1 of the study evaluated the efficacy and safety of Prexigebersen in conjunction with low dose cytarabine (LDAC), a therapeutic regimen well-established in the treatment of acute myeloid leukemia. The Stage 2 of the study is evaluating the efficacy and safety of Prexigebersen in conjunction with Decitabine in addition to the cohort evaluating Prexigebersen in conjunction with LDAC.

-- On January 18, a 1-for-20 reverse stock split was implemented.

Clinical Trials & Near-term Catalysts:

-- A phase II study of Prexigebersen, comprising of two Stages, in the treatment of acute myeloid leukemia is underway.
-- A phase IIa clinical study of Prexigebersen in combination with the frontline therapy, Dasatinib, for the treatment of chronic myeloid leukemia (CML) in accelerated and blast phase patients is ongoing.
-- A phase I clinical trial of Prexigebersen in patients with advanced solid tumors, including ovarian and uterine, pancreatic and hormone refractory breast cancer is expected to be initiated this year.
-- A phase I clinical trial of BP1002 in refractory or relapsed lymphoma and chronic lymphocytic leukemia (CLL) patients is anticipated to be initiated in 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT